NCT02384460View on ClinicalTrials.gov

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

PHASE3CompletedINTERVENTIONAL
Enrollment

169

Participants

Timeline

Start Date

March 11, 2015

Primary Completion Date

July 5, 2017

Study Completion Date

July 5, 2017

Conditions
Epidermolysis Bullosa
Interventions
DRUG

SD-101-6.0 cream

applied topically once a day for 90 days

DRUG

Placebo (SD-101-0.0) cream

applied topically once a day for 90 days

Trial Locations (38)

2217

Kogarah

3050

Parkville

3052

Parkville

5020

Salzburg

10032

New York

11733

East Setauket

19104

Philadelphia

20016

Washington D.C.

20122

Milan

27516

Chapel Hill

33136

Miami

33155

Miami

55455

Minneapolis

60611

Chicago

63110

St Louis

65212

Columbia

75015

Paris

78218

San Antonio

78723

Austin

80045

Aurora

85016

Phoenix

94063

Redwood City

98105

Seattle

03756

Lebanon

07601

Hackensack

45229-3039

Cincinnati

29425-5780

Charleston

0-06200

Nice

Unknown

Toulouse

Freiburg im Breisgau

Hanover

Tel Aviv

Kaunas

Warsaw

Belgrade

Madrid

9713 GZ

Groningen

WC1N 3JH

London

Sponsors

Collaborators (1)

Amicus Therapeutics
All Listed Sponsors
collaborator

Amicus Therapeutics

INDUSTRY

lead

Scioderm, Inc.

INDUSTRY